glutathione in ms vivo cortical response to oral fumarate therapy in relapsing-remitting multiple sclerosis: A single-arm open-label phase IV trial using 7-Tesla 1H MRS MS/MS spectra of the reactions

RTqPCR revealed expression of the hepatic markers A1AT , AFP, ALB , and ASGR1 as well as genes enriched in the liver such as APOA2 , TDO2 and TTR and xenobiotic metabolism, cytochrome P450 ( CYP) 3A4 and CYP3A7 (Supplementary Fig

Consistent with the trends in the symptoms, we found that bumetanide had significant effects over the 3-month treatment course on both GABA/NAA ( F 1,41 = 5.06, fdr.perm.p = 0.0418) and GABA/Glx ( F 1,41 = 6.16, fdr.perm.p = 0.0418) ratios in the IC and GABA/Glx ratio ( F 1,48 = 5.47, fdr.perm.p = 0.0418) in the VC when considering baseline MRS measurements as additional covariates (Fig

Ramos-Gonzlez EJ, Bitzer-Quintero OK, Ortiz G, Hernndez-Cruz JJ, Ramrez-Jirano LJ (2024) Relationship between inflammation and oxidative stress and its effect on multiple sclerosis

PMID: 16 StojanovicOMiguel-AliagaITrajkovskiM